[{"orgOrder":0,"company":"Andromaco","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHILE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Duloxetine Hydrochloride","moa":"Norepinephrine transporter","graph1":"Undisclosed","graph2":"Phase I","graph3":"Andromaco","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Granules","sponsorNew":"Andromaco \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Andromaco \/ Inapplicable"},{"orgOrder":0,"company":"Andromaco","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHILE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Duloxetine Hydrochloride","moa":"Norepinephrine transporter","graph1":"Undisclosed","graph2":"Phase I","graph3":"Andromaco","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Granules","sponsorNew":"Andromaco \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Andromaco \/ Inapplicable"},{"orgOrder":0,"company":"OWP Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Duloxetine Hydrochloride","moa":"Norepinephrine transporter | Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"OWP Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"OWP Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"OWP Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Esketamine Hydrochloride","moa":"||Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Esketamine Hydrochloride","moa":"||Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Duloxetine Hydrochloride","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alto Neuroscience \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Alto Neuroscience \/ Inapplicable"},{"orgOrder":0,"company":"Aarhus University Hospital","sponsor":"Central Denmark Region | University of Aarhus | Vejle Hospital | Aalborg University | TrygFonden | Independent Research Fund Denmark","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Duloxetine Hydrochloride","moa":"Norepinephrine transporter","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Aarhus University Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aarhus University Hospital \/ Central Denmark Region | University of Aarhus | Vejle Hospital | Aalborg University | TrygFonden | Independent Research Fund Denmark","highestDevelopmentStatusID":"11","companyTruncated":"Aarhus University Hospital \/ Central Denmark Region | University of Aarhus | Vejle Hospital | Aalborg University | TrygFonden | Independent Research Fund Denmark"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Duloxetine Hydrochloride","moa":"Norepinephrine transporter","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunnybrook Health Sciences Centre \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Sunnybrook Health Sciences Centre \/ Inapplicable"},{"orgOrder":0,"company":"Johns Hopkins University","sponsor":"National Institute of Arthritis and Musculoskeletal and Skin Diseases | Pacira BioSciences","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Duloxetine Hydrochloride","moa":"Norepinephrine transporter","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Johns Hopkins University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johns Hopkins University \/ National Institute of Arthritis and Musculoskeletal and Skin Diseases | Pacira BioSciences","highestDevelopmentStatusID":"10","companyTruncated":"Johns Hopkins University \/ National Institute of Arthritis and Musculoskeletal and Skin Diseases | Pacira BioSciences"},{"orgOrder":0,"company":"Scripps Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Duloxetine Hydrochloride","moa":"Norepinephrine transporter","graph1":"Neurology","graph2":"Phase II","graph3":"Scripps Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scripps Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Scripps Health \/ Inapplicable"},{"orgOrder":0,"company":"Rambam Health Care Campus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Duloxetine Hydrochloride","moa":"Norepinephrine transporter","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"Rambam Health Care Campus","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Pill","sponsorNew":"Rambam Health Care Campus \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Rambam Health Care Campus \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for Duloxetine Hydrochloride

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

cayman pipeline prospector

Contact Supplier

Access all COS suppliers
Check all USDMF suppliers

Contact Us
PharmaScopic.com

Duloxetine Hydrochloride

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

121 API Suppliers, 43 USDMF, 32 CEP/COS, 12 JDMF, 19 EU WC, 26 KDMF, 19 NDC API, 56 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

73 Drugs in Development

73 Drugs in Development

INTERMEDIATES

32 Intermediate Suppliers

32 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

600 FDF Dossiers, 98 FDA Orange Book, 282 Europe, 40 Canada, 18 Australia, 28 South Africa, 134 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

CAPSULE, DELAYED REL PELLETS;ORAL - EQ 20MG BASE, CAPSULE, DELAYED REL PELLETS;ORAL - EQ 30MG BASE, CAPSULE, DELAYED REL PELLETS;ORAL - EQ 60MG BASE

RELATED EXCIPIENT COMPANIES

3 Evonik, 1 Rochem International Inc, 16 SPI Pharma, 17 DKSH, 8 Boai NKY Pharmaceuticals Ltd, 4 Gangwal Healthcare, 7 Nanjing Well Pharmaceutical, 2 Pfanstiehl, 3 Kirsch Pharma, 4 ACG Worldwide, 6 Actylis, 1 Aeon Procare, 2 Alcedo Pharmachem, 7 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 3 Ashland, 35 BASF, 1 Clariant, 13 Corel Pharma Chem, 3 DFE Pharma, 2 Esteem Industries, 2 Finar, 14 Gangwal Chemicals, 9 Ideal Cures, 4 Ingredion Pharma Solutions, 22 Kerry, 1 Keval Exports, 3 Kima Chemical, 6 Lonza Capsugel, 13 Microlex e.U, 2 Nanjing Bold Chemical, 1 Nitika Pharmaceutical Specialities, 2 Nomisma Healthcare, 4 Novo Excipients, 2 Pharmatrans-Sanaq, 7 Pluviaendo, 2 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 2 Qualicaps, 11 Roquette, 14 Seppic, 7 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 5 Sigachi Industries, 2 Silverline Chemicals, 4 The Dow Chemical Company, 2 Ulanqab Kema New Material, 2 Valens Pharmachem, 2 Vasa Pharmachem, 2 Vertellus

EXCIPIENTS BY APPLICATIONS

70 Coating Systems & Additives, 70 Fillers, Diluents & Binders, 36 Solubilizers, 35 Disintegrants & Superdisintegrants, 33 Direct Compression, 33 Controlled & Modified Release, 29 Thickeners and Stabilizers, 28 Granulation, 22 Topical, 21 Taste Masking, 20 Parenteral, 19 Chewable & Orodispersible Aids, 17 Lubricants & Glidants, 16 Film Formers & Plasticizers, 11 Co-Processed Excipients, 9 Emulsifying Agents, 9 Empty Capsules, 7 API Stability Enhancers, 6 Rheology Modifiers, 6 Surfactant & Foaming Agents, 5 Coloring Agents, 4 Vegetarian Capsules

DIGITAL CONTENT

1 Data Compilation #PharmaFlow, 59 News #PharmaBuzz

GLOBAL SALES INFORMATION

21 US Medicaid Prescriptions, 216 Regulatory FDF Prices, 15 Annual Reports

MARKET PLACE

23 APIs, 7 FDF Dossiers

PATENTS & EXCLUSIVITIES

20 US Patents, 4 Health Canada Patents

REF. STANDARDS & IMPURITIES

3 EDQM, 11 USP, 12 Others

ANALYTICAL

2 BioAnalytical Methods, 2 Analytical Methods

Xls

Filters

×

filter

Company Name

filter

Year

filter

DEALS // DEV.

filter

Country

filter

Sponsor

filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

All Developments

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

Reset All

01

Dr. Reddy's Laboratories

India

CPhI WW Frankfurt

DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Lead Product(s) : Duloxetine Hydrochloride

Therapeutic Area : Undisclosed

Study Phase : Phase I

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Bioavailability Study of Duloxetine Delayed-Relase Capsules 60 mg Under Fed Condition

Details : Undisclosed

Product Name : Undisclosed

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

November 14, 2014

Lead Product(s) : Duloxetine Hydrochloride

Therapeutic Area : Undisclosed

Highest Development Status : Phase I

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Dr Reddy Company Banner

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

02

Dr. Reddy's Laboratories

India

CPhI WW Frankfurt

DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Lead Product(s) : Duloxetine Hydrochloride

Therapeutic Area : Undisclosed

Study Phase : Phase I

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Bioavailability Study of Duloxetine Delayed-Release Capsules 60 mg Under Fasting Condition

Details : Undisclosed

Product Name : Undisclosed

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

November 14, 2014

Lead Product(s) : Duloxetine Hydrochloride

Therapeutic Area : Undisclosed

Highest Development Status : Phase I

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Dr Reddy Company Banner

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

03

Sunnybrook Health Sciences Centre

Country

Peptide Process CMC

Not Confirmed

04

Aarhus University Hospital

Country

Peptide Process CMC

Not Confirmed

05

Johnson & Johnson Innovative Medicine

U.S.A

Peptide Process CMC

Not Confirmed

06

Scripps Health

Country

Peptide Process CMC

Not Confirmed

07

Rambam Health Care Campus

Israel

Peptide Process CMC

Not Confirmed

08

Andromaco

Country

Peptide Process CMC

Not Confirmed

09

Andromaco

Country

Peptide Process CMC

Not Confirmed

10

OWP Pharmaceuticals

U.S.A

Peptide Process CMC

Not Confirmed